MapLight Therapeutics Deemed Overvalued at 4.1x Book Value After 118% YTD Rally
Updated
Updated · Simply Wall St · Jul 27
MapLight Therapeutics Deemed Overvalued at 4.1x Book Value After 118% YTD Rally
1 articles · Updated · Simply Wall St · Jul 27
Summary
$36.56 MapLight shares were assessed as overvalued, with the stock trading at 4.1 times book value and a market capitalization near $1.66 billion.
That multiple tops both the 3.5x peer average and the 2.5x U.S. biotech level, showing investors are paying a premium for MapLight's CNS drug pipeline despite minimal revenue.
The premium comes even as forecasts point to losses over the next three years, with ongoing losses of about $199.48 million leaving the stock exposed if clinical trial results disappoint.
MapLight has still surged 118.01% year to date and 19.32% over 90 days, though a 3.46% drop in the past week suggests momentum has cooled after the recent rally.